Modulators of inflammation in Bronchopulmonary Dysplasia

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Over 50 years after its first description, Bronchopulmonary Dysplasia (BPD) remains a devastating pulmonary complication in preterm infants with respiratory failure and develops in 30–50% of infants less than 1000-gram birth weight. It is thought to involve ventilator- and oxygen-induced damage to an immature lung that results in an inflammatory response and ends in aberrant lung development with dysregulated angiogenesis and alveolarization. Significant morbidity and mortality are associated with this most common chronic lung disease of childhood. Thus, any therapies that decrease the incidence or severity of this condition would have significant impact on morbidity, mortality, human costs, and healthcare expenditure. It is clear that an inflammatory response and the elaboration of growth factors and cytokines are associated with the development of BPD. Numerous approaches to control the inflammatory process leading to the development of BPD have been attempted. This review will examine the anti-inflammatory approaches that are established or hold promise for the prevention or treatment of BPD.

Original languageEnglish (US)
Pages (from-to)459-470
Number of pages12
JournalSeminars in Perinatology
Volume42
Issue number7
DOIs
StatePublished - Nov 1 2018

Fingerprint

Bronchopulmonary Dysplasia
Inflammation
Lung
Morbidity
Mortality
Mechanical Ventilators
Health Expenditures
Birth Weight
Premature Infants
Respiratory Insufficiency
Health Care Costs
Lung Diseases
Intercellular Signaling Peptides and Proteins
Chronic Disease
Anti-Inflammatory Agents
Cytokines
Oxygen
Incidence
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Modulators of inflammation in Bronchopulmonary Dysplasia. / Savani, Rashmin C.

In: Seminars in Perinatology, Vol. 42, No. 7, 01.11.2018, p. 459-470.

Research output: Contribution to journalReview article

@article{7fd72a31a0ef46ae9b8e35dadfb9451c,
title = "Modulators of inflammation in Bronchopulmonary Dysplasia",
abstract = "Over 50 years after its first description, Bronchopulmonary Dysplasia (BPD) remains a devastating pulmonary complication in preterm infants with respiratory failure and develops in 30–50{\%} of infants less than 1000-gram birth weight. It is thought to involve ventilator- and oxygen-induced damage to an immature lung that results in an inflammatory response and ends in aberrant lung development with dysregulated angiogenesis and alveolarization. Significant morbidity and mortality are associated with this most common chronic lung disease of childhood. Thus, any therapies that decrease the incidence or severity of this condition would have significant impact on morbidity, mortality, human costs, and healthcare expenditure. It is clear that an inflammatory response and the elaboration of growth factors and cytokines are associated with the development of BPD. Numerous approaches to control the inflammatory process leading to the development of BPD have been attempted. This review will examine the anti-inflammatory approaches that are established or hold promise for the prevention or treatment of BPD.",
author = "Savani, {Rashmin C}",
year = "2018",
month = "11",
day = "1",
doi = "10.1053/j.semperi.2018.09.009",
language = "English (US)",
volume = "42",
pages = "459--470",
journal = "Seminars in Perinatology",
issn = "0146-0005",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Modulators of inflammation in Bronchopulmonary Dysplasia

AU - Savani, Rashmin C

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Over 50 years after its first description, Bronchopulmonary Dysplasia (BPD) remains a devastating pulmonary complication in preterm infants with respiratory failure and develops in 30–50% of infants less than 1000-gram birth weight. It is thought to involve ventilator- and oxygen-induced damage to an immature lung that results in an inflammatory response and ends in aberrant lung development with dysregulated angiogenesis and alveolarization. Significant morbidity and mortality are associated with this most common chronic lung disease of childhood. Thus, any therapies that decrease the incidence or severity of this condition would have significant impact on morbidity, mortality, human costs, and healthcare expenditure. It is clear that an inflammatory response and the elaboration of growth factors and cytokines are associated with the development of BPD. Numerous approaches to control the inflammatory process leading to the development of BPD have been attempted. This review will examine the anti-inflammatory approaches that are established or hold promise for the prevention or treatment of BPD.

AB - Over 50 years after its first description, Bronchopulmonary Dysplasia (BPD) remains a devastating pulmonary complication in preterm infants with respiratory failure and develops in 30–50% of infants less than 1000-gram birth weight. It is thought to involve ventilator- and oxygen-induced damage to an immature lung that results in an inflammatory response and ends in aberrant lung development with dysregulated angiogenesis and alveolarization. Significant morbidity and mortality are associated with this most common chronic lung disease of childhood. Thus, any therapies that decrease the incidence or severity of this condition would have significant impact on morbidity, mortality, human costs, and healthcare expenditure. It is clear that an inflammatory response and the elaboration of growth factors and cytokines are associated with the development of BPD. Numerous approaches to control the inflammatory process leading to the development of BPD have been attempted. This review will examine the anti-inflammatory approaches that are established or hold promise for the prevention or treatment of BPD.

UR - http://www.scopus.com/inward/record.url?scp=85056706341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056706341&partnerID=8YFLogxK

U2 - 10.1053/j.semperi.2018.09.009

DO - 10.1053/j.semperi.2018.09.009

M3 - Review article

VL - 42

SP - 459

EP - 470

JO - Seminars in Perinatology

JF - Seminars in Perinatology

SN - 0146-0005

IS - 7

ER -